［1］Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs ［J］. N Engl J Med, 1981, 305(3): 139-153.
［2］Horan PG, McMullin MF, McKeown PP. Anthracycline cardiotoxicity ［J］. Eur Heart J, 2006, 27(10): 1137-1138.
［3］Ramasamy R, Yan SF, Schmidt AM. Rage: therapeutic target and biomarker of the inflammatory response—the evidence mounts ［J］. J Leukoc Biol, 2009, 86(3): 505-512.
［4］Yan SF, Ramasamy R, Schmidt AM. The rage axis: a fundamental mechanism signaling danger to the vulnerable vasculature ［J］. Circ Res, 2010, 106(5): 842-853.
［5］Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (rage) and cardiovascular disease ［J］. Expert Rev Mol Med, 2009, 11: e9.
［6］Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity ［J］. Circulation, 2005, 111(13): 1601-1610.
［7］Bertinchant JP, Polge A, Juan JM, et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings ［J］. Clin Chim Acta, 2003, 329(1-2): 39-51.
［8］Tao KZh, Chen EY, Jiang ZL, et al. Effects of advanced glycation end products on aortic smooth muscle cell of STZ-induced diabetic rat ［J］. Acta Anatomic Sinica, 2000, 31(40): 327-331.（in Chinese）
陶凯忠，陈尔瑜，姜宗来，等.晚期糖化终产物对糖尿病大鼠主动脉平滑肌细胞的影响 ［J］. 解剖学报，2000, 31(4): 327-331.
［9］Zhang H, Zhao W, Wang RL, et al. Immunohistochemical analysis of AGEs, TGF-β1 and CTGF in diabetic rat lungs ［J］. Acta Anatomic Sinica, 2008, 39(6): 910-914.（in Chinese）
张宏，赵伟，王瑞琳，等. 实验性糖尿病大鼠肺组织AGEs、TGF-β1、CTGF免疫组织化学分析 ［J］.解剖学报，2008, 39(6): 910-914.
［10］Ramasamy R, Yan SF, Schmidt AM. Stopping the primal rage reaction in myocardial infarction: capturing adaptive responses to heal the heart ［J］? Circulation, 2008, 117(25): 3165-3167.
［11］Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management ［J］. J Am Coll Cardiol, 2009, 53(24): 2231-2247.
［12］Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection ［J］. Lancet Oncol, 2009, 10(4): 391-399.
［13］Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity ［J］. Cell Biol Toxicol, 2007, 23(1): 15-25.
［14］Outomuro D, Grana DR, Azzato F, et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem ［J］? Int J Cardiol, 2007, 117(1): 6-15.
［15］Mantawy EM, El-Bakly WM, Esmat A, et al. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis ［J］. Eur J Pharmacol, 2014, 728C: 107-118.
［16］Guo RM, Xu WM, Lin JC, et al. Activation of the P38 MAPK/Nf-Kappab pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells ［J］. Mol Med Rep, 2013, 8(2): 603-608.
［17］Bruynzeel AM, Abou El Hassan MA, Schalkwijk C, et al. Anti-inflammatory agents and monoher protect against dox-induced cardiotoxicity and accumulation of Cml in mice ［J］. Br J Cancer, 2007, 96(6): 937-943.
［18］Rojas A, Perez-Castro R, Gonzalez I, et al. The emerging role of the receptor for advanced glycation end products on innate immunity ［J］. Int Rev Immunol, 2014, 33(1): 67-80.
［19］Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond ［J］. J Leukoc Biol, 2013, 94(1): 55-68. 
［20］Zhu J, Zhang J, Xiang D, et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity ［J］. Eur J Pharmacol, 2010, 643(2-3): 247-253.
［21］Guo J, Ananthakrishnan R, Qu W, et al. Rage mediates podocyte injury in adriamycin-induced glomerulosclerosis ［J］. J Am Soc Nephrol, 2008, 19(5): 961-972.